Navigation Links
Rise in Mercury Levels in Supermarket Fish
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Rise Mercury Levels Supermarket Fish

(Date:5/17/2008)...ampaign on Behalf of CSL Behring, maker of Zema...ntation Therapy, K...a Biggs, a fashion,designer and actress who appear... an education campaign on behalf of CSL Behring, a...ntitrypsin (AAT) deficiency,after her own diagnosi...
(Date:5/16/2008)... Law Offices of Howard G. Smith,announces a June 9... the,securities class action lawsuit filed on beha...red the common stock of Inverness Medical,Innovati...Amex: IMA ) in the,Company,s secondary public off...riod"). The shareholder lawsuit is pending in the ...
(Date:5/16/2008)...critics want agency to act, not wait years , ...o-consumer drug ads on television should include a... to report adverse side effects, U.S. health exper...anel that advises the U.S. Food and Drug Administr...the FDA for print ads. At Friday,s meeting, the pa...
(Date:5/16/2008)..., WASHINGTON, May 16 /PRNewswire-USNewswire/ -- M...nicians in the Greater Portland, Oregon and,Vancou...r contract as,Teamsters., "The Teamsters are plea... contract that gives them job protection and a sec...sident Jim Hoffa., The workers, both full-time an...
Breaking Medicine News(10 mins):Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc. 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3
...rly 360 mobile teams have been pressed into servic...k the outbreak of water-borne and other seasonal d..."There was always a possibility of the outbreak of...because of the presence of moisture in the atmosph...
...hough weight lost can be lost in several ways, not... high-fiber whole grain cereal diet is one of the ... in the Journal of the American Dietetic Associati...ls not only help to lose weight but also gain some...
...revious survey of approximately 5,000 United Kingd...ercent of women reported habitual or regular snori... gender, obesity, excessive daytime sleepiness, in...and mechanical obstruction in the upper airway. Ad...
...ecent study in rats proposes that the highly malig...lows them to convert into highly mobile cells// , ...nvironment. According to the Duke Comprehensiv...g of the two alternating forms of tumor cells; tra...
Other Medicine News:Health News:Weight Loss Healthier with a Diet of Whole Grain Cereals 2Health News:Prevalence of Self-reported Snoring, Sleep-disordered Breathing in Military 2Health News:Cancer cell behavior during Metastasis – New finding 2Health News:Cancer cell behavior during Metastasis – New finding 3
(Date:5/16/2008)...resentations at ASCO Annual Meeting Will Further D... in Front-line Multiple Myeloma -, CAMBRIDGE, Mas...als,The Takeda Oncology Company, today announced ...heduled to be featured at the 2008 American Societ...icago, Illinois, May 30 -,June 3, 2008. The data w...
(Date:5/16/2008)...akers include industry and customer thought leader... Inc., the recognized,leader and trusted resource ...sted a constellation of prestigious academic medic...tners at its annual user group meeting in San,Fran... to internally and,collaboratively manage thousand...
(Date:5/16/2008)... Include:, -- Results demonstrating that TYKERB a...eaningful extension of progression-free survival (...ck both the inside and,outside of the HER2 recepto...ta demonstrating activity of TYKERB alone despite ...f trastuzumab and chemotherapy, LONDON and PHILAD...
(Date:5/16/2008)....J., May 16 /- Veridex, LLC announced... Corporation of America Holdings,(LabCorp), has co...r,prostate cancer. The new assay uses the biologic...ncer, detecting the methylation of the gene,GST-Pi... primarily in,cancer. Veridex is developing the me...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Hormone Replacement May Cut Risk for Age Linked Eye Disease 16759 1Hormone Replacement May Cut Risk for Age Linked Eye Disease 16759 2Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 1Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 2Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 3Consumer Watchdog Gives HMO Regulator 10 Days to Order Reinstatement of Patients Whose Policies Have Been Illegally Cancelled 16750 1Consumer Watchdog Gives HMO Regulator 10 Days to Order Reinstatement of Patients Whose Policies Have Been Illegally Cancelled 16750 2Clues to ancestral origin of placenta emerge in Stanford study 2886 1Clues to ancestral origin of placenta emerge in Stanford study 2886 2Clues to ancestral origin of placenta emerge in Stanford study 2886 3
... WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstC... and Medicine at Georgetown,University Medical Cen...es of Neurochem Inc.,s North American Phase III cl...present today an update on,Neurochem,s investigati...mer,s disease (AD). The presentation by Dr. Aisen ...
... ~ Valopicitabine achieved both primary and second...raction was observed between,valopicitabine and ri...wire-FirstCall/ -- Idenix,Pharmaceuticals, Inc. to...ed to evaluate triple combination therapy, consist...candidate for the,treatment of hepatitis C, pegyla...
Other Medicine Technology:At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6
...ected curve trial lenses are ground with the same ...nd are invaluable in treating low vision patients....rs contain a disproportionately large number of le... to produce, and fewer lenses in the higher power ...
simplified focusing guidance system has made the LM-770 the easiest instrument to use of its type. Technicians can be trained to operate the LM-770 with a minimum of instruction. The instrument tells
...on electronic refractor to its line of Vision Diag...ce of a wireless, infrared remote control and is p...s. The Evolution gives the practitioner complete c...eld remote control. With the Evolution, the practi...
Marco Radiusgauges are available with either a standard or digital display as well as in either monocular or binocular form. All offer the functions of two instruments in one, measuring both the curv
Medicine Products: